Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM383 PK and Safety Study in Healthy Subjects
NCT07292688Phase 1Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CM383 in Alzheimer's disease (AD) (3 arms), sponsored by Keymed Biosciences. Primary endpoint: Pharmacokinetics at Day 85. Started Jan 2026; status: recruiting.
02
Drugs
CM383
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07292688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292688.